Skip to main content

Multiple Myeloma

In-Depth Treatment Profile, Multiple Myeloma, Oncology, Bispecific Antibodies

Ongoing Analyses and Recent Data for Talvey in Multiple Myeloma

Rohan Vashi, PharmD, MSc

Multiple Myeloma, Conference Highlights ASCO, Oncology

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO, Oncology

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma

FDA Approvals, Multiple Myeloma, Oncology

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Oncology

Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

Multiple Myeloma, Oncology, Bispecific Antibodies

Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma

Wayne Kuznar

Multiple Myeloma, Oncology

CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma

Chase Doyle

Multiple Myeloma, Oncology

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Page 1 of 6
Results 1 - 10 of 53